CNSP

CNS Pharmaceuticals, Inc. NASDAQ Listed Nov 8, 2019

Healthcare ·Biotechnology ·US · cnspharma.com

$7.10

After hrs $7.28 -0.14%

Mkt Cap $4.1M

52w Low $1.90 15.8% of range 52w High $34.80

50d MA $2.85 200d MA $5.87

P/E (TTM) -0.1x

EV/EBITDA 0.3x

P/B 0.2x

Debt/Equity 0.1x

ROE -350.5%

P/FCF -0.2x

RSI (14) —

ATR (14) —

Beta 0.49

50d MA $2.85

200d MA $5.87

Avg Volume 32.7K

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

SIC Code

2834

CIK (SEC)

1729427

Phone

800 946 9185

2100 West Loop South · Houston, TX 77027 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 31, 2026	AMC	-5.37	-10.15	-89.0%	2.39	+12.1%	-4.6%	-5.4%	-2.9%	-8.8%	-8.8%	—
Nov 14, 2025	AMC	-6.63	-5.76	+13.1%	6.90	-3.0%	-2.9%	-2.5%	-2.5%	-5.7%	+0.0%	—
Aug 14, 2025	AMC	-9.60	-6.42	+33.1%	6.03	+4.6%	-15.6%	+2.7%	-10.3%	+15.6%	+0.7%	—
Nov 14, 2024	AMC	-0.10	-150.06	-9999.0%	71.40	-0.3%	-11.6%	+0.8%	+6.6%	+3.9%	+9.2%	—
Aug 14, 2024	AMC	-3585.43	-4033.61	-12.5%	83.16	-5.5%	+1.7%	-4.3%	+4.2%	+22.8%	+19.8%	—
May 15, 2024	AMC	—	-12304.92	—	5988.00	-3.8%	+12.7%	+8.7%	+8.2%	+7.7%	+3.7%	—
Apr 1, 2024	AMC	-57000.00	-28511.40	+50.0%	10794.00	+0.1%	-14.5%	-18.7%	-21.8%	-28.1%	-37.7%	—
Nov 14, 2023	AMC	-51900.00	-32412.97	+37.5%	50100.00	+4.2%	+15.0%	+25.7%	+59.9%	+47.3%	+25.1%	—
Aug 14, 2023	AMC	-84600.00	-31212.48	+63.1%	53100.00	-1.1%	-3.4%	+2.8%	+6.2%	+2.3%	-31.1%	—
May 15, 2023	AMC	—	-77731.09	—	41700.00	-2.9%	-10.8%	-7.9%	-2.9%	+14.4%	+27.3%	—
Mar 31, 2023	AMC	-6000.00	-2.23	+100.0%	30000.00	-6.0%	-2.0%	-8.0%	-13.4%	-25.0%	-25.1%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Sep 12	Maxim Group	Upgrade	Hold → Buy	—	$7.52	$7.82	+4.0%	-1.7%	+22.3%	+21.5%	+16.1%	+16.2%
Mar 25	Maxim Group	Downgrade	Buy → Hold	—	$40.56	$18.12	-55.3%	-51.8%	-58.3%	-60.9%	-61.5%	-59.8%
Feb 2	Brookline Capital	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Aug 24	Ladenburg Thalmann	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Dec 4	Benchmark	Maintains	Speculative Buy → Buy	—	—	—	—	—	—	—	—	—

Data updated apr 25, 2026 2:20am · Source: massive.com